-
European Review For Medical and... 2014
Topics: Aged; Analgesics, Opioid; Anesthetics, Local; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Arthropods; Bites and Stings; Chlorpheniramine; Edema; Erythema; Humans; Hydrocortisone; Lidocaine; Male; Pain; Pentazocine; Tetanus Toxoid
PubMed: 24763894
DOI: No ID Found -
Turkish Journal of Pharmaceutical... Aug 2018In this study, we aimed to develop and optimize an anti-allergic cream containing dexamethasone and chlorpheniramine using the design of experiments (DoE) method. The...
OBJECTIVES
In this study, we aimed to develop and optimize an anti-allergic cream containing dexamethasone and chlorpheniramine using the design of experiments (DoE) method. The optimized product was investigated for its physicochemical properties and therapeutic effects in rabbits.
MATERIALS AND METHODS
The creams were formulated using the simple mixing process, which was optimized by the Design Expert software. The products were then evaluated the properties such as pH, skin diffusion profile, short-term stability, qualitative, and assay, using the newly validated UV-Vis spectrophotoscopy quantitative method. efficacy tests in rabbits of the best products were compared with the marketed Phenergan (promethazine 2%).
RESULTS
The UV-Vis method used to simultaneously determine the amount of both dexamethasone and chlorpheniramine was successfully developed and validated. Using the DoE method, it was clear that the release profile of dexamethasone depended on the amount of sodium lauryl sulfate, propylene glycol, and DMSO. In contrast, only DMSO affected the release pattern of chlorpheniramine. The best formulation was optimized by the software. The product showed acceptable parameters in pH (5.7±0.1), short-term stability over 10 days, and skin diffusion profiles of 20.47±1.25% and 4.92±0.42% after 40 min for dexamethasone and chlorpheniramine, respectively. In addition, the product demonstrated no observable inflammatory response in the experimental animals. Also, it illustrated 2-fold better anti-allergic efficacy than the marketed product (i.e., 27.2 compared with 43.4 min in the recovery time).
CONCLUSION
We were successful in developing and optimizing an anti-allergic cream containing dexamethasone and chlorpheniramine. The best product satisfied all required parameters. Interestingly, our product showed higher efficacy than Phenergan. These results can be a background for further clinical trials.
PubMed: 32454657
DOI: 10.4274/tjps.91885 -
American Family Physician Jun 2003Pregnant women commonly use over-the-counter medications. Although most over-the-counter drugs have an excellent safety profile, some have unproven safety or are known... (Review)
Review
Pregnant women commonly use over-the-counter medications. Although most over-the-counter drugs have an excellent safety profile, some have unproven safety or are known to adversely affect the fetus. The safety profile of some medications may change according to the gestational age of the fetus. Because an estimated 10 percent or more of birth defects result from maternal drug exposure, the U.S. Food and Drug Administration has assigned a risk category to each drug. Many drugs have not been evaluated in controlled trials and probably will not be because of ethical considerations. Of the commonly used over-the-counter medications, acetaminophen, chlorpheniramine, kaolin and pectin preparations, and most antacids have a good safety record. Other drugs, such as histamine H2-receptor blockers, pseudoephedrine, and atropine/diphenoxylate should be used with caution. If use of smoking cessation products is desired, the intermediate-release preparations minimize the amount of nicotine while maintaining efficacy. With all over-the-counter medications used during pregnancy, the benefit of the drug should outweigh the risk to the fetus.
Topics: Female; Fetus; Humans; Maternal-Fetal Exchange; Nonprescription Drugs; Pregnancy; Risk Factors
PubMed: 12825840
DOI: No ID Found -
Current Issues in Molecular Biology Aug 2023The first-generation antihistamine chlorpheniramine (CPA) is believed to have both anxiolytic and antidepressant properties. The current study sought to assess the...
Forced Swimming-Induced Depressive-like Behavior and Anxiety Are Reduced by Chlorpheniramine via Suppression of Oxidative and Inflammatory Mediators and Activating the Nrf2-BDNF Signaling Pathway.
The first-generation antihistamine chlorpheniramine (CPA) is believed to have both anxiolytic and antidepressant properties. The current study sought to assess the mechanisms behind the antidepressant and anxiolytic effects of CPA therapy concerning oxidative stress, inflammation, and nuclear factor p45 for erythroid 2-Brain-derived neurotrophic factor (Nrf2-BDNF) signaling pathway in forced swimming-induced depressive-like behavior and anxiety. Eighteen male Wistar rats (180-200 gm) rats were separated into three groups (n = 6): a stressed group (acute stress) that underwent the forced swimming test (FST) and a stressed group that received pretreatment with CPA (10 mg/kg body weight) for 3 weeks (CPA + acute stress). Animals were subsequently put through the following behavioral tests after undergoing a forced swim test (FST) for 5 min: an immobility test, open field test, and elevated plus maze test. Serum cortisol levels were measured when the rats were euthanized at the end of the experiments. Brain neurotransmitters (cortisol, serotonin, and noradrenaline), oxidative stress (SOD and MDA), inflammatory (IL-6 and IL-1) biomarkers, and the Nrf2-BDNF signaling pathway in the hippocampus and cerebral cortex tissues was determined. CPA prevented stress-induced increases in cortisol levels ( < 0.0001), decreased brain neurotransmitters, and increased oxidative stress and inflammation. CPA also upregulated the Nrf2-BDNF signaling pathway. Thus, CPA mitigates depressive-like behavior and anxiety by inhibiting oxidative stress and inflammation and upregulating the Nrf2-BDNF signaling pathway in the brain tissues.
PubMed: 37623226
DOI: 10.3390/cimb45080407 -
EClinicalMedicine Sep 2021Although tinnitus has a prevalence between 20 and 42.8%, the currently recommended management for tinnitus, such as tinnitus support and psychologic therapies, are...
BACKGROUND
Although tinnitus has a prevalence between 20 and 42.8%, the currently recommended management for tinnitus, such as tinnitus support and psychologic therapies, are relatively time-consuming and expensive. Several new pharmacologic treatments designed for tinnitus patients without specific origin had been developed but their efficacy remains unclear.
METHODS
The current Network Meta-Analysis (NMA) of randomised controlled trials (RCTs) was conducted to evaluate the efficacy of different pharmacologic treatments for tinnitus management in tinnitus patients without specific or treatable origin (i.e. primary tinnitus). Databases were searched from inception to April 5, 2021. All network meta-analytic procedures were conducted under the frequentist model. We calculated the effect size of outcomes with different rating scales with standardized mean difference. PROSPERO registration: CRD42020177742.
FINDINGS
Overall, 36 RCTs were included with 2,761 participants. The main results revealed that pharmacologic interventions with brain-acting effect (for example, amitriptyline, acamprosate, and gabapentin) and those with anti-inflammation/anti-oxidant effect (for example, intra-tympanic dexamethasone injection plus oral melatonin) were associated with superior improvement in tinnitus severity and response rate compared to placebo/control. Oral amitriptyline were associated with the highest improvement in tinnitus severity and the fourth highest response rate. None of the investigated interventions was associated with different changes in quality of life compared to placebo/control. All the investigated treatments were associated with similar drop-out rate to placebo/control.
INTERPRETATION
The current NMA suggests a potential role for treatments with brain-acting effect (for example, amitriptyline, acamprosate, and gabapentin) or anti-inflammation/anti-oxidant effect (for example, intra-tympanic dexamethasone injection plus oral melatonin) as the preferable effective treatments for tinnitus without specific or treatable origin.
FUNDING
none.
PubMed: 34611615
DOI: 10.1016/j.eclinm.2021.101080 -
Journal of Family Medicine and Primary... Oct 2022Antihistamines (AHs) are the most widely long-term therapeutic option to manage allergic diseases. This research aimed to study the effects of long-term administration...
CONTEXT
Antihistamines (AHs) are the most widely long-term therapeutic option to manage allergic diseases. This research aimed to study the effects of long-term administration of AHs: on cognitive (memory, mood, attention, sleep and executive function) and psychomotor performance.
MATERIALS AND METHODS
This prospective, observational study for a total duration of 30 months was carried out at the Dermatology OPD in adult patients with dermatological condition who were newly prescribed either chlorpheniramine (4 mg, BD), levocetirizine (10 mg, OD), fexofenadine (180 mg, OD) or bepotastine (10 mg, BD) for at least 28 days as per inclusion and exclusion criteria after taking written informed consent. A detailed history of the patients, memory (using PGI memory scale) and psychomotor functions, Brief Mood Introspection Scale and Epworth Sleepiness Scale were assessed at baseline, 1 week and 4 weeks. Data obtained were analysed using paired sample -test and one-way ANOVA followed by post hoc analysis (-value <0.05 statistically significant).
RESULTS
A total of 22 in chlorpheniramine group, 23 in levocetirizine group, 20 in fexofenadine group and 18 in bepotastine group were analysed. Chlorpheniramine and levocetirizine had deteriorating effects on cognitive and psychomotor performance, whereas fexofenadine and bepotastine showed positive effect on various cognitive and psychometric tasks. The study results showed chlorpheniramine and levocetirizine to be having sedative effects, whereas fexofenadine was nonsedating. In bepotastine group, no effect on sleep was observed. No significant difference in mood scores was observed in between chlorpheniramine, levocetirizine and fexofenadine groups. In bepotastine group, arousal calm and positive tired scores increased at 4 week as compared to baseline.
CONCLUSION
Patients with dermatological illnesses can be prescribed fexofenedine and bepotastine, as compared to chlorpheniramine and levocetirizine, and their cognitive and psychological functions should be evaluated periodically with suitable tests.
PubMed: 36618177
DOI: 10.4103/jfmpc.jfmpc_77_22